Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Prostatic Diseases: early-phase trial registry

3 of 4 indexed Prostatic Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Prostatic Diseases: 4 US clinical trials tracked, 3 recruiting.

Prostatic Diseases is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Blue Earth Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition prostatic-diseases

OPEN 3 | RECR 75% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Prostatic Diseases (this)75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Prostatic Diseases

Prostatic Diseases lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostatic Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostatic Diseases is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12Phase 41

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 4 1

Named interventions

Most-linked intervention names on Prostatic Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Standard CBSM Behavioral
1 trials
Cultural CBSM Behavioral
1 trials
18F-rhPSMA-7.3 injection (in phase 1 only) Diagnostic test
1 trials
Lutetium (177Lu) rhPSMA-10.1 Injection Drug
1 trials
18F-Fluciclovine PET/CT Scan Drug
1 trials
Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617 Drug
1 trials
Pocenbrodib Drug
1 trials

US sites by state

Facility locations filed on Prostatic Diseases trials. A trial with sites in several states counts in each.

Florida 3 trials
Nebraska 2 trials
California 2 trials
Virginia 1 trials
Texas 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostatic Diseases page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Diseases condition card totals 4 registered trials; most-linked intervention Standard CBSM; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.